Mar 27 2012
Moberg Derma AB (STO:MOB) has entered into a distribution agreement with
Pharmaplan (Pty) Ltd. for Nalox™//Emtrix® - for discolored and damaged
nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the
agreement Pharmaplan is granted exclusive rights to market and sell
Nalox™ /Emtrix® in South Africa. Moberg Derma assumes production and
supply responsibility.
"The agreement is part of our international commercialization of Nalox™
/Emtrix®. We are looking forward to make the product available to the
patients in South Africa through the cooperation with Pharmaplan", says
Peter Wolpert, President and CEO of Moberg Derma.